LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

21.29 -4.79

Buy Sell

Overview

Share price change

24h

Current

Min

21.29

Max

23.06

Key metrics
By Trading Economics
Income	202M 274M
Sales	5.4M 284M
P/E Sector Avg	9.565 49.8
Profit margin	96.33
Employees	796
EBITDA	-21M 26M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+45.34% upside

Market Stats
By TradingEconomics
Market Cap	-385M 3.8B
Previous open	26.08
Previous close	21.29

News Sentiment

By Acuity

18%

82%

34 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

14.845 / N/A Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 May 2026, 23:41 UTC

Earnings

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 May 2026, 21:40 UTC

Earnings

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 May 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 May 2026, 23:13 UTC

Earnings

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 May 2026, 23:13 UTC

Earnings

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 May 2026, 23:12 UTC

Earnings

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 May 2026, 23:11 UTC

Earnings

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 May 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 May 2026, 23:07 UTC

Earnings

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 May 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 May 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 May 2026, 23:05 UTC

Earnings

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 May 2026, 23:04 UTC

Earnings

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 May 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 May 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 May 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 May 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 May 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 May 2026, 21:58 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 May 2026, 21:47 UTC

Market Talk

Earnings

Costco Posts 13% Sales Growth in April -- Market Talk

6 May 2026, 21:46 UTC

Earnings

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 May 2026, 21:40 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 May 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 May 2026, 21:32 UTC

Hot Stocks

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 May 2026, 21:29 UTC

Earnings

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

45.34% upside

12 Months Forecast

Average 32.25 USD 45.34%

High 40 USD

Low 24 USD

Based on 14 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

34 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.